International Stem Cell (ISCO) Asset Writedowns and Impairment (2011 - 2026)
International Stem Cell (ISCO) posted quarterly Asset Writedowns and Impairment of $1.4 million for Q4 2019, up 467.07% year-over-year from $246000.0 in Q4 2018, and up 467.07% quarter-over-quarter from $246000.0 in Q4 2018.
International Stem Cell (ISCO) Asset Writedowns and Impairment (2011 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Asset Writedowns and Impairment for 9 consecutive years, with $1.4 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Asset Writedowns and Impairment rose 467.07% year-over-year to $1.4 million; the TTM figure through Sep 2024 stood at $1.4 million (changed N/A YoY), while the FY2024 annual figure was $2000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment advanced to $1.4 million in Q4 2019 per ISCO's latest filing, from $246000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.4 million in Q4 2019 and bottomed at $2000.0 in Q2 2016.
- Historically, Asset Writedowns and Impairment has averaged $245533.3 across 5 years, with a median of $93000.0 in 2018.
- Annual changes were most pronounced in 2016 — Asset Writedowns and Impairment tumbled 96.15% — and 2017, when it soared 3804.17%.
- International Stem Cell's Asset Writedowns and Impairment stood at $77000.0 in 2015, then plunged by 68.83% to $24000.0 in 2016, then jumped by 3804.17% to $937000.0 in 2017, then slumped by 73.75% to $246000.0 in 2018, then soared by 467.07% to $1.4 million in 2019.
- Business Quant data shows ISCO's Asset Writedowns and Impairment at $1.4 million in Q4 2019, $246000.0 in Q4 2018, and $157000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111,000.00 |
| Jun 30, 2026 | 111,000.00 |
| Dec 31, 2019 | 1.40 Mn |
| Dec 31, 2019 | 1.40 Mn |
| Dec 31, 2018 | 246,000.00 |
| Dec 31, 2018 | 246,000.00 |
| Sep 30, 2018 | 157,000.00 |
| Sep 30, 2018 | 157,000.00 |
| Jun 30, 2018 | 93,000.00 |
| Jun 30, 2018 | 93,000.00 |
| Mar 31, 2018 | 111,000.00 |
| Mar 31, 2018 | 111,000.00 |
| Dec 31, 2017 | 937,000.00 |
| Dec 31, 2017 | 937,000.00 |
| Sep 30, 2017 | 158,000.00 |
| Sep 30, 2017 | 158,000.00 |
| Mar 31, 2017 | 80,000.00 |
| Mar 31, 2017 | 80,000.00 |
| Dec 31, 2016 | 24,000.00 |
| Dec 31, 2016 | 24,000.00 |